@article{IR,
      author = {Gutierrez, Anthony and Gandhi, Arpita and Kaempf, Andy and  Saultz, Jennifer N. and Xie, Wei and Cook, Rachel and  Migdady, Yazan and Schachter, Levanto and Slater, Susan and  Meyers, Gabrielle and Maziarz, Richard T.},
      url = {http://digitalcollections.ohsu.edu/record/41302},
      title = {Overall survival in myelofibrosis treated with allogeneic  hematopoietic cell transplant is impacted by reversal of  marrow fibrosis: a single institution experience from  Oregon Health & Science University},
      publisher = {Oregon Health and Science University},
      abstract = {Allogeneic hematopoietic cell transplantation (allo HCT)  is the only curative therapy for patients with  intermediate-2 or high risk myelofibrosis (MF). We sought  to examine the impact of pre-HCT splenomegaly, splenic RT,  and marrow fibrosis on overall survival (OS). Subjects with  primary or secondary MF who underwent allo HCT using  matched related (n=10) or unrelated (n=24) donor grafts,  PBSC (n=33) or marrow (n=1), between 2005 and 2021 were  identified. Median follow-up was estimated by reverse  Kaplan-Meier (KM). Marrow fibrosis regression (defined as  any decrease in grade) and GVHD were considered  time-varying predictors. Time-to-engraftment and OS were  modeled by Cox regression, while post-HCT death rates were  estimated via the extended KM method. Logistic regression  was used to model fibrosis regression by a specified time  point. Our data on engraftment, GVHD, and survival are  comparable to that reported by the CIBMTR with this  analysis demonstrating a strong correlation between aGVHD,  lack of marrow fibrosis regression, and increased risk of  death. Novel strategies, such as the use of peri-HCT JAK  inhibition and T cell depletion (in-and ex-vivo), may  provide rapid marrow remodeling and improve OS in MF  patients.},
      number = {IR},
      doi = {https://doi.org/10.6083/bpxhc41302},
      recid = {41302},
      address = {2023-07-19},
}